FORMULATION DEVELOPMENT AND EVALUATION OF ORAL DISINTEGRATING TABLET OF CANDESARTAN CILEXETIL.
Lokesh Kumar*, Virendra Singh and Rakesh Kumar Meel
Abstract
Candesartan cilexetil is selective AT1 subtype angiotensin II receptor
and it is used in treatment of hypertension, heart failure and myocardial
infarction. The oral disintegrating tablets as recently developed drug
delivery system. Candesartan cilexetil should be administrated orally
once or twice daily for a total daily dose of 4 to 32 mg. In this
investigation oral disintegrating tablet were prepared by using super
disintegrating agent crospovidone, croscaremellose sodium, sodium
starch glycolate in concentration 3%, 4%, 5%. Sweeteners and flavors
were used to enhance the organoleptic properties of tablet. Tablets
were prepared by direct compression technique. Formulated oral
disintegrating tablets were evaluated for weight variation, friability,
disintegration time, drug content, wetting time, water absorption ratio
and in vitro drug release. The results show that the all formulations
satisfied the limits of oral disintegrating tablet. The formula [F9] that contain 5%
crospovidone as superdisintegrant shows the best results with a disintegrating time 31 sec,
hardness 3.7 kg/cm2 and drug release rate 98.08% within 10 min.
Keywords: Candesartan cilexetil, oral disintegrating tablet, crospovidone.
[Full Text Article]